"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A study comparing 2 scans to see how well treatment works for advanced kidney cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This study compared results from CT scans and a type of PET-CT scan for people having treatment for advanced kidney cancer. The research team wanted to see if PET-CT scans could help show how well treatment was working.
More about this trial
They all had a type of PET-CT scan called an 18F-RGD PET-CT scan and a CT scan before, during and after treatment. They had an injection of a radioactive tracer before the PET-CT scan. This helps show up the cancer’s blood supply on the scan.
The researchers hoped that the amount of tracer taken up by the cancer would be linked to the size of the cancer, and show how well the treatment was working.
The aim of this study was to see if 18F-RGD PET-CT scans could be used to see how well treatment for kidney cancer is working.
Summary of results
This study recruited 10 people with renal cell cancer (kidney cancer) that had spread to another part of the body. The research team had hoped to recruit more people, but they were unable to and had to close the trial earlier than planned.
They had scans before treatment (scan 1), during treatment (scan 2) and after treatment (scan 3). The research team looked at the amount of radioactive tracer that was taken up by the cancer on the PET-CT scans. They compared this to the size of the cancer on the CT scans. They wanted to see if there was a link between the two measurements.
They found that the change in the amount of tracer taken up by the cancer between scan 1 and scan 2, was related to the change in the size of the cancer.
But the change in the amount of tracer taken up by the cancer between scan 1 and scan 3, was not related to the change in the size of the cancer.
No one taking part had any serious side effects from the tracer injection.
The research team found that it was difficult to draw any firm conclusions because of the small number of people who took part in the study
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Fergus Gleeson
Experimental Cancer Medicine Centre (ECMC)
Oxford University Hospitals NHS Trust